TEL AVIV, Israel, March 5, 2015 (GLOBE NEWSWIRE) -- BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced today that Colin Foster, President and Chief Executive Officer of BioBlast Pharma, will provide a corporate overview at the 27th Annual ROTH Conference.
| ROTH Capital Markets Investor Conference | |
| Date: | March 10 |
| Time: | 9:00-9:30am Pacific Time |
| Location: | Ritz Carlton, Dana Point, CA |
| Webcast: | http://wsw.com/webcast/roth29/orpn/ |
About BioBlast Pharma Ltd.
BioBlast Pharma is a clinical-stage biotechnology company committed to developing clinically meaningful therapies for patients with rare and ultra-rare genetic diseases. Founded in 2012, the company is rapidly building a diverse portfolio of product candidates with the potential to address unmet medical needs for incurable genetic diseases. The BioBlast platforms are based on deep understanding of the disease-causing biological processes, and potentially offer solutions for several diseases that share the same biological pathology.